

Alternative donor transplantation for acute myeloid leukemia in patients aged ≥ 50 years: young HLA-matched unrelated or haploidentical donor?

Miguel-Angel Perales,^{1*} Benjamin Tomlinson,^{2*} Mei-Jie Zhang,^{3,4} Andrew St. Martin,³ Amer Beitinjaneh,⁵ John Gibson,⁶ William Hogan,⁷ Natasha Kekre,⁸ Hillard Lazarus,² David Marks,⁹ Joseph McGuirk,¹⁰ Rizwan Romee,¹¹ Melhem Solh,¹² John E. Wagner,¹³ Daniel J. Weisdorf,¹⁴ Marcos de Lima² and Mary Eapen³

*MAP and BT share first authorship

¹Adult Bone Marrow Transplant Services, Department of Medicine, Memorial Sloan-Kettering Cancer Center, and Department of Medicine, Weill Cornell Medical College, New York, NY, USA; ²Seidman Cancer Center, University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, OH, USA; ³Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA; ⁴Division of Biostatistics, Institute for Health and Society, Medical College of Wisconsin, Milwaukee, WI, USA; ⁵UM Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA; ⁶Institute of Haematology, Royal Prince Alfred Hospital, Camperdown, NSW, Australia; ⁷Bone Marrow Transplant Program, Mayo Clinic, Rochester, MN, USA; ⁸Blood and Marrow Transplant Program, The Ottawa Hospital, Ottawa, ON, Canada; ⁹University Hospitals Bristol National Health Service Foundation Trust, Bristol, UK; ¹⁰Division of Hematologic Malignancies and Cellular Therapy, University of Kansas Medical Center, Kansas City, KS, USA; ¹¹Division of Hematologic Malignancies and Transplantation, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; ¹²The Blood and Marrow Transplant Program at Northside Hospital, Atlanta, GA, USA; ¹³BMT Program, University of Minnesota Masonic Children's Hospital, Minneapolis, MN, USA and ¹⁴University of Minnesota Medical Center, Minneapolis, MN, USA

©2020 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol.2018.215202

Received: December 21, 2018.

Accepted: May 16, 2019.

Pre-published: May 17, 2019.

Correspondence: MARY EAPEN - meapen@mcw.edu

First allogeneic transplant for AML in the US, 2008-2015	Haploidentical donor		Matched unrelated donor	
	Excluded	Remaining	Excluded	Remaining
Donor <ul style="list-style-type: none"> Haploidentical (≥ 2 HLA MM) Matched unrelated donor (8/8) 		771		2458
Select patients ≥ 50 years old	323	448	1074	1384
Select BM and PBSC	59 <ul style="list-style-type: none"> Cord blood (56) Multiple donors (3) 	389	22 <ul style="list-style-type: none"> Cord blood (22) 	1362
Exclude patient older than 80 years	1	388	1	1361
GVHD prophylaxis: <ul style="list-style-type: none"> Haploidentical: Post-transplant cyclophosphamide + calcineurin inhibitor + mycophenolate Matched unrelated donor: Calcineurin inhibitor + mycophenolate or calcineurin inhibitor + methotrexate 	136 <ul style="list-style-type: none"> CD34 selected (39) Ex-vivo T-cell depletion (34) In-vivo T-cell depletion (28) Other (35) 	252	68 <ul style="list-style-type: none"> CD34 selected (17) In-vivo T-cell depletion (42) Other (9) 	1293
Select common conditioning regimens for unrelated donor transplant <ul style="list-style-type: none"> Busulfan + Cyclophosphamide Busulfan + Fludarabine Melphalan + Fludarabine 	0	252	292 <ul style="list-style-type: none"> TBI + Cy (92) TBI + Flud (97) TBI + other (33) Cy + other (23) Bu + other (31) Other (16) 	1001
Exclude unrelated donors older than 40 years	0	252	182 <ul style="list-style-type: none"> 40 - 50 (142) 51 - 60 (40) 	819
Exclude patients not in remission	60	192	188	631